Real-World Use of Once-Weekly Semaglutide in Thai Patients With Type 2 Diabetes Mellitus in a Private Hospital Setting.
Yotsapon ThewjitcharoenNalin YenseungSiriwan ButadejSoontaree NakasatienPhawinpon ChotwanviratWaralee ChatchomchuanEkgaluck WanothayarojSirinate KrittiyawongThep HimathongkamPublished in: Journal of the ASEAN Federation of Endocrine Societies (2023)
In this single center undertaking, it was shown that in among persons with T2DM and obesity in Thailand, semaglutide was associated with short-term glycemic control and weight loss comparable with what has been observed in randomized clinical trials and other RWE.
Keyphrases
- weight loss
- glycemic control
- type diabetes
- bariatric surgery
- end stage renal disease
- ejection fraction
- healthcare
- insulin resistance
- blood glucose
- newly diagnosed
- roux en y gastric bypass
- chronic kidney disease
- prognostic factors
- health insurance
- peritoneal dialysis
- patient reported outcomes
- clinical trial
- adipose tissue
- weight gain
- emergency department
- physical activity
- adverse drug